Skip to main content
. Author manuscript; available in PMC: 2020 Aug 1.
Published in final edited form as: Eur J Nucl Med Mol Imaging. 2019 Jun 7;46(9):1952–1965. doi: 10.1007/s00259-019-04357-w

Fig. 5.

Fig. 5

Regional time–activity curves: (a) [18F]UCB-J baseline scan; (b) [18F]UCB-J self-blocking scan (with 0.15 mg/kg of UCB-J); (c) [18F]UCB-J baseline scan followed by displacement with levetiracetam (30 mg/kg, given i.v. at 90 min); (d) baseline scan with (S)-5-[18F]3